Jennifer L. Yates , David S. Palat , M. Kristina Subik , William T. Lee , Kathleen A. McDonough , Edward Conuel
{"title":"Pharmacokinetics of convalescent plasma therapy in a COVID-19 patient with X-linked Agammaglobulinemia","authors":"Jennifer L. Yates , David S. Palat , M. Kristina Subik , William T. Lee , Kathleen A. McDonough , Edward Conuel","doi":"10.1016/j.clicom.2022.03.001","DOIUrl":"10.1016/j.clicom.2022.03.001","url":null,"abstract":"<div><p>Convalescent plasma (CP) has been the first line of defense against numerous infectious diseases throughout history. The COVID-19 pandemic created a need for a quick, easily accessible, and effective treatment for severe disease and CP was able to meet that immediate need. The utility of CP warrants a better understanding of the pharmacokinetics of CP treatment. Here we present the case of a COVID-19 patient with a genetic deficiency in antibody production who received CP as a part of the treatment regimen. In depth serological analysis revealed a surprising lack of SARS-CoV-2 specific antibodies and reduced serum IgG following CP infusion. Our study highlights plasma dilution and accelerated antibody clearance as potential mechanisms for the variable efficacy of CP therapy.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000075/pdfft?md5=34b22391e8ffa6c7a82920a0541e41ef&pid=1-s2.0-S2772613422000075-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82836497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Melissa A. Hausburg , Jason S. Williams , Kaysie L. Banton , Charles W. Mains , Michael Roshon , David Bar-Or
{"title":"C1 esterase inhibitor-mediated immunosuppression in COVID-19: Friend or foe?","authors":"Melissa A. Hausburg , Jason S. Williams , Kaysie L. Banton , Charles W. Mains , Michael Roshon , David Bar-Or","doi":"10.1016/j.clicom.2022.05.001","DOIUrl":"10.1016/j.clicom.2022.05.001","url":null,"abstract":"<div><p>From asymptomatic to severe, SARS-CoV-2, causative agent of COVID-19, elicits varying disease severities. Moreover, understanding innate and adaptive immune responses to SARS-CoV-2 is imperative since variants such as Omicron negatively impact adaptive antibody neutralization. Severe COVID-19 is, in part, associated with aberrant activation of complement and Factor XII (FXIIa), initiator of contact system activation. Paradoxically, a protein that inhibits the three known pathways of complement activation and FXIIa, C1 esterase inhibitor (C1-INH), is increased in COVID-19 patient plasma and is associated with disease severity. Here we review the role of C1-INH in the regulation of innate and adaptive immune responses. Additionally, we contextualize regulation of C1-INH and SERPING1, the gene encoding C1-INH, by other pathogens and SARS viruses and propose that viral proteins bind to C1-INH to inhibit its function in severe COVID-19. Finally, we review the current clinical trials and published results of exogenous C1-INH treatment in COVID-19 patients.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000130/pdfft?md5=6f60ce312e700d2ba460726f6edaab12&pid=1-s2.0-S2772613422000130-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73573642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Reduced immune system responsiveness in fibromyalgia - A pilot study","authors":"Sophia Björkander , Malin Ernberg , Indre Bileviciute-Ljungar","doi":"10.1016/j.clicom.2022.02.003","DOIUrl":"10.1016/j.clicom.2022.02.003","url":null,"abstract":"<div><p>Fibromyalgia is characterized by widespread musculoskeletal and joint pain, stiffness, fatigue, and sleep and mood disorders. However, the involvement of the immune system in the pathways of fibromyalgia is unclear. The aim of this study was to explore the role of the immune system in comparison with healthy controls and in association with clinical symptoms. Thirteen women with fibromyalgia and 14 controls were included. Peripheral blood mononuclear cells were stimulated and analysed by flow cytometry, and interferon gamma (IFN-γ) and interleukins were measured. Among clinical symptoms, the fibromyalgia group showed decreased cold pain threshold. Immunologically, they had a higher percentage of monocytes, a lower percentage of CD19<sup>+</sup> B<em>-</em>cells, and lower secretion of IFN-γ after stimulation. Decreased capacity to secrete IFN-γ was significantly correlated with decreased cold pain threshold in the fibromyalgia group. These results confirm the presence of immune aberrations in fibromyalgia, at least partially responsible for the associated pain.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000063/pdfft?md5=f52a4a08e3ba783db8bbe070c073ee4f&pid=1-s2.0-S2772613422000063-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74085625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lily H. Sung MD , Natalya Surmachevska DO , Jose E. Rubio MD
{"title":"A case of de novo seronegative inflammatory oligoarthritis associated with COVID-19 infection","authors":"Lily H. Sung MD , Natalya Surmachevska DO , Jose E. Rubio MD","doi":"10.1016/j.clicom.2022.10.001","DOIUrl":"10.1016/j.clicom.2022.10.001","url":null,"abstract":"<div><p>Infection with SARS-CoV-2 (COVID-19) virus is characterized by an acute respiratory viral illness, often accompanied by extrapulmonary manifestations. Musculoskeletal symptoms such as myalgias and arthralgias are observed in 60 – 70% of cases. Inflammatory arthritis associated with SARS-CoV-2 infection has been reported in the literature, however, nearly all such cases describe a post-viral or reactive phenomenon occurring a few weeks following the infection. We report a unique case of de novo arthritis at the onset of a confirmed COVID-19 infection in a 55-year-old woman. Magnetic resonance imaging demonstrated synovial enhancement consistent with synovitis. Her disease was deemed refractory after failing several immunosuppressive agents. Lastly, we compare our patient's clinical presentation with two other similar cases to understand the natural history of this emerging syndrome.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000269/pdfft?md5=601396304a130f4447ba2991fca02e7a&pid=1-s2.0-S2772613422000269-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73455612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Elisabeth Mara, Tobias Mader, Johannes Gratzer, Stefanie Hochegger, Thomas Pekar
{"title":"SARS-CoV-2 antibody determination in a vaccinated and recovered cohort in Austria","authors":"Elisabeth Mara, Tobias Mader, Johannes Gratzer, Stefanie Hochegger, Thomas Pekar","doi":"10.1016/j.clicom.2022.08.001","DOIUrl":"10.1016/j.clicom.2022.08.001","url":null,"abstract":"<div><p>Since December 2019 the world has been dealing with a severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic. The first SARS-CoV-2 vaccine was made available in Europe at the end of 2020. 202 volunteers from the vicinity of the University of Applied Sciences Wiener Neustadt took part in this study; their IgG levels recognizing the RBD of SARS-CoV-2 were determined. The aim was to evaluate the SARS-CoV-2 titer levels of vaccinated, recovered and vaccinated plus recovered persons. We could show that there is a significant difference in the antibody levels of vaccinated, vaccinated plus recovered and only recovered probands. Additionally, the highest antibody levels were found in triple vaccinated persons. Furthermore, the Moderna vaccine seems to have a higher immune response.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000178/pdfft?md5=6a8905db5e40cc3a617c40902259b813&pid=1-s2.0-S2772613422000178-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85284856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Khouloud Ferchichi , Imen Aouinti , Ahmed Zaiem , Ghozlane Lakhoua , Widd Kaabi , Ons Charfi , Sarrah Kastalli , Riadh Daghfous , Sihem El Aidli
{"title":"Myocarditis following Coronavirus vaccination","authors":"Khouloud Ferchichi , Imen Aouinti , Ahmed Zaiem , Ghozlane Lakhoua , Widd Kaabi , Ons Charfi , Sarrah Kastalli , Riadh Daghfous , Sihem El Aidli","doi":"10.1016/j.clicom.2022.11.001","DOIUrl":"10.1016/j.clicom.2022.11.001","url":null,"abstract":"<div><h3>Introduction</h3><p>Myocarditis is an adverse reaction discovered after the marketing of SARS-CoV-2 mRNA vaccines. Nevertheless, this effect is not mentioned as an adverse reaction in the summary of product characteristics of other types of vaccines against this disease.</p></div><div><h3>Objective</h3><p>In this work, we aim to present the cases of myocarditis after vaccination against COVID-19 reported to the national Tunisian centre of pharmacovigilance.</p></div><div><h3>Method</h3><p>We present the cases of myocarditis reported after the COVID-19 vaccination. All cases are diagnosed according to Brighton's case definition of myocarditis. The vaccines causality assessment was estimated by the French imputability updated method of Bégaud et al.</p></div><div><h3>Results</h3><p>We included five patients. The sex ratio (M/F) was 4. The mean age was 30 years. All patients had no notable cardiovascular history and did not report any significant past medical history. The onset of symptoms was two days post-vaccination in three patients. The predominant reported symptoms are chest pain and dyspnea in the five cases. Cardiac magnetic resonance imaging (MRI) confirmed the myocarditis diagnosis in four patients (not performed for one patient).</p><p>All cases were classified as definitive cases according to the Brighton case definition of myocarditis. No patient required hospitalization in a cardiac intensive care unit. All the patients recovered from acute myocarditis within a few days.</p></div><div><h3>Conclusion</h3><p>Reported cases of myocarditis post-COVID-19 vaccination in our population are rare, not severe, and have a quick favorable outcome.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000270/pdfft?md5=69501bc1319cb7b5556cfb9f79c46041&pid=1-s2.0-S2772613422000270-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84157430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Priscila Rezeck Nunes , Mariana Romao-Veiga , Maria Terezinha Serrao Peracoli , Jose Carlos Peracoli , Valeria Cristina Sandrim
{"title":"Potential role of uric acid to activate NLRP3 inflammasome triggering endothelial dysfunction in preeclampsia","authors":"Priscila Rezeck Nunes , Mariana Romao-Veiga , Maria Terezinha Serrao Peracoli , Jose Carlos Peracoli , Valeria Cristina Sandrim","doi":"10.1016/j.clicom.2022.03.003","DOIUrl":"10.1016/j.clicom.2022.03.003","url":null,"abstract":"<div><p>Preeclampsia (PE) is a pregnancy-related disorder associated with increasing maternal death rates and affecting 2–8% of pregnant women worldwide. Arterial hypertension and proteinuria, followed by other maternal dysfunctions are classic clinical parameters to identify this disease. Furthermore, hyperuricemia is strictly related to PE, and high plasmatic levels of uric acid have been associated with disease severity. The inflammation in the endothelium caused by danger signals, such as uric acid crystals, is persistent and stimulates the release of inflammatory cytokines, and activates the NLRP3 inflammasome. The mechanisms underlying endothelial dysfunction induced by the metabolism of uric acid, and consequently increased levels of inflammation and oxidative stress in women with PE could be ameliorated with interventions related to inhibition of the NLRP3 activation MSU-mediated and may improve the prognostics of this disease.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000099/pdfft?md5=2abae82803dace4956bc669db3ddfbd1&pid=1-s2.0-S2772613422000099-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90294927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mengyuan Guo , Zhaohui Wang , Rui Yang , Kun Liu , Junchao Zeng , Tianhui An
{"title":"High neutrophil/lymphocyte ratio and low lymphocyte percentage are independent risk factors for new-onset CKD","authors":"Mengyuan Guo , Zhaohui Wang , Rui Yang , Kun Liu , Junchao Zeng , Tianhui An","doi":"10.1016/j.clicom.2022.11.003","DOIUrl":"10.1016/j.clicom.2022.11.003","url":null,"abstract":"<div><p>Chronic kidney disease (CKD) is one of the major public health problems worldwide, and inflammation is a noticeable cause of CKD. A total of 5508 non-CKD patients were enrolled in our prospective study and followed for three years, with 1.25% (<em>n</em> = 69) participants having newonset CKD at the endpoint. After adjustment for potential confounders, we found that High NLR and low LYMPH% are two independent risk factors for new-onset CKD: Compared with the lowest NLR tertile, the multifactor corrected OR (95% CI) of the highest tertile was 2.47(1.20–5.09), <em>P</em> = 0.014; And adjusted OR (95% CI) was 0.31(0.16–0.62) for the highest LYMPH% tertile, <em>P</em> = 0.001. The model constructed with NLR, LYMPH%, and other risk factors had favourable predictive power for new-onset CKD with an AUC of 0.82 (95% CI, 0.76–0.88). Assessment of NLR and LYMPH% may be helpful for early warning of CKD occurrence.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000294/pdfft?md5=f75317f6ec969ade80737d050d6208a6&pid=1-s2.0-S2772613422000294-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83313350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Meningoradiculitis post-COVID-19 mRNA vaccination: A case report","authors":"Alexandre Landry , Stéphanie Crapoulet , Luc H. Boudreau , Christine Bourque , Lyle Weston , Nicholas Pilote , Guillaume Desnoyers , Ludivine Chamard-Witkowski","doi":"10.1016/j.clicom.2022.03.004","DOIUrl":"10.1016/j.clicom.2022.03.004","url":null,"abstract":"<div><p>We present a rare case of meningoradiculitis occurring after mRNA COVID-19 vaccination.</p><p>This patient, with a history of inflammatory arthritis following rubella vaccination, presented to the emergency department 4 days after her vaccination with both central and radicular nervous system symptoms. Symptoms included pain, sensory and motor deficits in L5 roots distribution, along with signs of central irritation, such as headache, difficulty concentrating and a Babinski sign. MRI showed bilateral L5 nerve roots enhancement. Lumbar puncture showed elevated protein and IgG, and relevant serologies excluded common causes. Prednisone and physical therapy helped the patient to achieve near complete recovery nine weeks after presentation.</p><p>We concluded that this patient presented meningoradiculitis probably secondary to her vaccination in a context of possible overactive immune system. While such presentations might be rare, and do not constitute a general reason to abstain from vaccination, they must be well recognized and treated.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000105/pdfft?md5=3a42b22b1b8337eb4f2e493f37c1fab0&pid=1-s2.0-S2772613422000105-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89045166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}